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INTRODUCTION
20

h Century saw the emergence of the

"medical mass tort" as a legal construct, a media opportunity, and a
staple for products liability litigators. Drug and device litigation
spawned innovations in the law as it grappled with the complex issues presented by each new product; market-share liability (DES
litigation), Daubert challenges (Bendectin litigation), and courtappointed science panels (breast implant litigation)' are just a few
examples. But the issues faced by medical manufacturers in this
Century promise to be as interesting and as challenging as those of
the past. Patient privacy, marketing and promotional practices,
physician-industry conflicts of interest, the continuing evolution of
the learned intermediary doctrine, and reuse of "single-use" medical devices will be among the major themes of drug and device litigation in the future.
II.

ONLINE PHARMACEUTICAL SALES

The boom in e-commerce has generated expanded consumer
demand for prescription drugs over the internet. The convenience
of home delivery, along with the discounts offered by many pharmacy sites, make online purchasing very appealing.4 Among the
benefits of online medication purchasing are:
-greater availability of drugs for shut-in people or those who
do not live near a pharmacy
-comparative shopping among sites in order to find the lowest prices
-greater convenience and a larger variety of products
-greater, faster access to written information relating to

1. Sindell v. Abbott Laboratories, 26 Cal. 3d 588, cert. denied, 449 U.S. 912
(1980).
2. Daubert v. Merrell-Dow Pharms., Inc., 509 U.S. 579 (1994).
3. In re Breast Implant Litig., No. CV 92-P-10000-S (N.D. Ala. 1998)
4. Jeri Clausing, Online Pharmacies Try to Fend Off Government Regulation, N. Y
Times, March 21, 2000, at Al8.
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medications
-the privacy of buying medical products from home5
But the increased volume of online drug buying raises concerns over the privacy of patient medical information, the physician's involvement (if any) in a patient's medication decisions,
and-as "rogue" sites selling "prescription-free" drugs proliferatethe regulatory and legal compliance of suppliers.
A.

Regulatory Overview

Enforcement of the laws and regulations that apply to online
pharmacies involves a tangle of state and federal agencies. Pharmacies have traditionally been regulated by the states,7 but the
internet exceeds the reach of any one state's laws; while state agencies can seek to enjoin online sites from doing business in their
state, they still remain open for business in the other 49 states. Further, while more scrupulous sites like Drugstore.com have obtained
pharmacy licenses in all 50 states,8 others are licensed in just onebut sell to all comers, in whatever state they reside. To avoid
charges of practicing medicine and dispensing drugs without a license in the other states, these sites argue that a customer, by visiting the site, actually enters the state where the site is licensed. 9
This argument has yet to be tested in court, however.
Given the limited powers of the state agencies, the FDA and
the Federal Trade Commission play key roles at the national level
by regulating drug claims and enforcing the Food, Drug, and Cosmetic act.
Customs and the Postal Service also help regulate
shipments of drug products." But regulating Internet pharmacy
sites, as an online seller of Viagra put it, is "kind of like trying to
nail Jell-O to a wall."" Sites can show up on the Web and then dis5. John Henkel, Buying Drugs Online, 34 FDA Consumer 25, 26 (JanuaryFebruary 2000).
6. Id. at 27.
7. Jeri Clausing, Online Pharmacies Try to Fend Off Government Regulation, N.Y.
Times, March 21, 2000, at Al8.
8.
Id.
9.
Sheryl Gay Stolberg, In Internet Drug Deals, a Regulation Dilemma, N. Y.

Times, June 27, 1999, www.nytimes.com/library/tech/99/06/biztech/articles//27net.html.
10.

John Henkel, Buying Drugs Online, 34 FDA Consumer 25, 27 (January-

February 2000).
11. Id.
12. Sheryl Gay Stolberg, In Internet Drug Deals, a Regulation Dilemma, N.Y
Times, June 27, 1999.
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appear overnight. In many cases, all that is needed to set up an
online drugstore is a valid doctor's license, a relationship with a
drug wholesaler, and a credit card, making regulatory oversight the
equivalent of trying to hold back the ocean with a dike made of
sand. 13
B.

The Absence Of A "LearnedIntermediary"

Many of the "online pharmacies" only require purchasers to fill
out a questionnaire to obtain medications, bypassing the traditional
requirement of a physician's prescription. Such sites usually claim
that questionnaires are reviewed by a doctor-but rarely is any information provided about who the doctor is and what his or her
credentials are. 14 Most of the time, patients do not learn who their
doctors are until the drugs arrive in the mail.'5 Further, if a consumer is convinced that he or she needs a particular treatment,
questionnaire answers may be falsified with relative ease." Thus,
while the questionnaire may save a trip to the doctor's office, the
time savings is very likely outweighed by the increased risk of harm.
According to Jeffrey Shuren, M.D., a medical officer in the FDA's
Office of Policy, Planning, and Legislation, "Patients risk obtaining
an inappropriate medication and may sacrifice the opportunity for
a correct diagnosis or the identification of a contraindication to the
drug.""
An example shows just how grave the consequences can be. In
Illinois, a 52-year-old man with a history of chest pains and a family
history of heart disease bought
S .
18Viagra from a site only requiring
that he fill out a questionnaire. The man later died of a heart attack. 9 While no connection between the drug and the man's death
has been shown, it is nevertheless unlikely that he would have been
able to obtain the drug had he seen his doctor, given his cardiac
risk factors. 20 This scenario raises the question whether the manu13. Id.
14. John Henkel, Buying Drugs Online, 34 FDA Consumer 25, 27 (JanuaryFebruary 2000).
15. Sheryl Gay Stolberg, In Internet Drug Deals, a Regulation Dilemma, N.Y.
TimesJune 27, 1999.
16. John Henkel, Buying Drugs Online, 34 FDA Consumer 25, 27 (JanuaryFebruary 2000).
17. Id. at 26.
18. Id.
19. Id.
20. Id.
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facturer should have any liability when the decedent would not
have received the drug had he sought it through legal channels.
The pharmacy industry has recently undertaken efforts at selfregulation in order to impose accountability and quality assurance
on Internet sales of prescription drugs. The National Association
of Boards of Pharmacy (NABP) recently introduced a certification2
program, '"Verified Internet Pharmacy Practice Sites" or "VIPPS. 1
Certification under VIPPS requires online pharmacy sites to maintain all their state licenses in good standing, to allow information
about them to be posted on the VIPPS website, and to allow inspec22
tions by the NABP. The VIPPS certification program is the "carrot" offered by the NABP; but they appear ready to wield the stick if
necessary. According to Carmen Catizone, executive director of
the organization, "Any site that uses a questionnaire without
a le23
gitimate patient-physician relationship, we consider illegal."
The American Medical Association ("AMA") is also taking
steps to remedy the lack of standards governing online prescribing.
At its June, 1999 annual meeting, the AMA discussed guidelines
dealing specifically with Internet prescriptions, which included a
requirement that patients first receive an in-person physical exami24
nation. Manufacturers voiced support for the AMA's efforts. Martin Hirsch, public affairs director for Roche, makers of Xenical -a
popular weight-loss drug frequently sold at sites not requiring a
prescription-indicated that "[t]he relationship between physician
and patient is critically important" and expressed Roche's support
25
for "guidelines that will ensure that this relationship continues.,
Manufacturers are clearly concerned about the liability implications of consumers buying their products without a doctor visit.
Not only will the practice result in injuries stemming from inappropriate prescriptions, it will bring increased pressure to provide
direct warnings to consumers, where now manufacturers need only
warn doctors under the "learned intermediary" doctrine. In August, 1998, when the Viagra craze was in full swing, Pfizer filed a
complaint with the Federal Trade Commission alleging that online
sites are deceiving consumers by ignoring the label's advice that the

21. Id. at 29.
22. Id.
23. Sheryl Gay Stolberg, In, Internet Drug Deals, a Regulation Dilemma, N.Y.
Times, June 27, 1999.
24. Id.
25. Id.

Published by Mitchell Hamline Open Access, 2000

5

LAW
WilliamWILLIAM
Mitchell LawMITCHELL
Review, Vol. 27,
Iss. 1REVIEW
[2000], Art. 25

drug be prescribed only after a physical examination.

[Vol. 27:1

26

C. Illegal Off-Shore Drug Sales

Recognizing the regulatory slipperiness of online drug sales,
the Clinton administration is seeking more Federal oversight of
online drugstores.2 7 The President is requesting legislation that
would require online drug sellers to get FDA approval before
transacting sales on the Web. 2s The legislation would also create
civil penalties of up to $500,000 for selling drugs without a prescription or without FDA certification. 29 The administration is also
seeking $10 million from Congress to beef up its enforcement of
online drug sales. °
But increased regulation at the Federal level may only result in
more sites moving their operations overseas, joining the numerous
foreign "pharmacies" already online selling drugs unavailable without a prescription-or unavailable altogether-in the U.S. According to Customs Service Commissioner Raymond W. Kelly, "Em] any
of these internet pharmacies are fly-by-night operations set up over31
seas to avoid U.S. law. They have little regard for patient safety.,
Many of the sites also sell products that are either different from
32
those approved in the U.S. or are past their expiration dates. Im-

ported drugs may be especially dangerous, according to one Customs official, because "[a] lot of this stuff is being cooked up in
somebody's back room
in Thailand" and "may be laced with all
33
sorts of contaminants.

The U.S. and Thai governments recently joined forces to shut
down seven prescription-drug-selling web sites operating in Thailand, the first-ever bust of a foreign online drug-selling operation. 4
26. Sheryl Gay Stolberg, In Internet Drug Deals, a Regulation Dilemma, N.Y
Times, June 27, 1999.
27. Jeri Clausing, Online Pharmacies Try to Fend Off Government Regulation, N.Y.
Times, March 21, 2000.
28. Robert Pear, Controls Sought on Drug Sales on the Internet, N. Y. Times, December 28, 1999.
29. Id.
30. Id.
31. Robert Pear, Thais Help U.S. Stem Internet Sales of Medicines, N.Y Times,
March 21, 2000.
32. John Henkel, Buying Drugs Online, 34 IDA Consumer 25, 27 (JanuaryFebruary 2000).
33. Robert Pear, Help U.S. Stem Internet Sales of Medicines, NY. Times, March 21,

2000.
34.

Id.
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One of the Thai sites, Vitality Health Products, advertised "prescription-free pharmaceuticals by e-mail at incredibly low prices"
and sold popular drugs like Minoxidil, Propecia, Viagra, Retin-A,
and Premarin. 3 5 The Website even advised customers what to do in
the event customs seized their shipment:
The bust, orchestrated by Thai police and the Thai equivalent
of the FDA, netted 20 computers, 245 parcels destined for the U.S.,
and more than 2.5 million pounds of drugs-including anabolic
steroids, Valium, Viagra, fen-phen, Tylenol with codeine, and
Xanax. 37 But the Thai operations appear to have been the tip of
the iceberg. Numerous similar sites continue selling prescription
drugs unabated from bases in Mexico, Switzerland, Britain, New
38
Customs seized nearly 10,000 packages
Zealand, and elsewhere.
containing prescription drugs in 1999, 4.5 times more than in the
previous year. The drugs seized either had not been approved in
the U.S., did not comply with FDA labeling requirements, or fell
below federal standards for the quality and purity of drugs. 9
Customs acknowledges that the number of pills seized probably represents only a fraction of the total volume of prescription
drugs being imported due to Internet sales. Frequently the orders
are sent in nondescript packages that do not declare their contents,
making detection difficult.4' And enforcement resources are limited: a spokesman for Customs indicates that the agency usually refrains from taking action when consumers import small amounts of
arrest Granny just because she wants
drugs, noting that "[w] e won't
42
to get her drugs cheaper.,
The illegal sale of expired or contaminated products, often
without prescription, may create complex products liability issues
for drug manufacturers, such as:
To what extent are manufacturers responsible for injuries suffered by people who obtained their drugs illegally?
Must manufacturers act to shut down such illegal distribution

35. Id.
36. Id.
37. Id.
38. Id. One site, "Direct Response Marketing," runs its operations from the
Channel Islands. http://www.directresponsemarketing.co.uk/.
39. Robert Pear, Online Sales Spur Illegal Importing of Medicine, N.Y Times,January 10, 2000.
40. Id.
41. Id.
42. Id.
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channels when they become aware of them?
What liability, if any, does a manufacturer have for injuries resulting from its product when the product has been contaminated
or "laced" with another substance by a third party outside normal
distribution?
Can the "learned intermediary" defense still be used if there
was no intermediary?
Does the manufacturer have a duty to warn these users directly, even though obtaining the drug without a doctor's prescription is illegal?
Courts will increasingly have to confront these thorny questions as illegal on-line sales of prescription drugs continue to grow.
D. Privacy

The confidentiality of private medical information will become
a greater concern as more and more prescriptions are filled over
the Web. One of the most popular uses of the Internet is for
health information, and this has led many web-users to submit personal medical information to unsecured chat-rooms and healthrelated sites.43 In addition, doctors and patients are increasingly
communicating by e-mail; hospitals are providing patients access to
their medical records on-line; and some health plans are even enrolling new members over the Internet. 4 While many of the larger
sites use secure servers and encrypt personal information, more
marginal sites do not. In this manner, personal health information
can become accessible to insurance companies, would-be employers, and others who could use it to their advantage.
Of particular concern with respect to online drug purchases
are "cookies," which many retail websites use to track the buying
habits of visitors to their sites. 5 While "cookies" can provide consumers the convenience of information and products tailored to
their interests, and eliminate the need for a log-in with every visit to
the site, they could also show that a customer was buying a particular drug on a continuing basis. In this manner, a customer's buying
habits could reveal that he has the virus that causes AIDS, or suffers
from depression, impotence, or any number of other conditions he
43. Milt Freudenheim, Privacy a Concern as Medical Industry Turns to Internet,
N.Y Times, August 12, 1998.
44. Id.
45. Margaret A. Winkler, M.D., et al., Guidelinesfor Medical and Health Information Sites on the Internet, 283JAMA 1600, 1605 (2000).
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would rather have kept private.4 6
Privacy issues do not present a significant liability concern for
drug and device manufacturers, who are usually blind to the identities of end-users of their products. Retailers, however, could end
up paying steep damages awards if they seek to profit from the sale
of confidential medical information, or otherwise fail to protect the
privacy of their customers.
III. DIRECT-TO-CONSUMER ADVERTISING: DEATH-KNELL FOR THE
LEARNED INTERMEDIARY DOCTRINE?

Relationships among healthcare manufacturers, doctors, patients, and payers have been transformed in recent years by increased competition, the cost-sensitivities of managed care, and
growing patient involvement in health care decisions. In particular, the old hierarchy for communicating information about prescription drugs-from manufacturer to doctor to patient-is being
subverted. In the era of managed care, physicians no longer control demand for prescription drugs to the degree they once did;
they must answer to their employers and to payers, who often are
reluctant to try new products-particularly if the cost of the new
treatment is higher than its predecessor. Therefore, recognizing
that consumers are more than ever driving the demand for prescription drugs, manufacturers are increasingly promoting their
products directly to public and bypassing the "filter" traditionally
applied by the medical community.
A.

Regulatoiy Requirements

drug advertising for the accuracy
FDA regulates prescription
•
47
While accuracy is a relatively
and adequacy of their content.
straightforward requirement, adequacy can be more complex. The
Food, Drug and Cosmetic Act requires that advertisements for prescription drugs include information "in brief summary" relating to
48
side effects, contraindications, and effectiveness of the drug. By
the time a manufacturer has complied, however, the summary is often far from brief. Other code provisions direct that the brief
summary must disclose side effects, contraindications, warnings,
46. Milt Freudenheim, Privacy a Concern as Medical Industry Turns to Internet,
N.Y. Times (August 12, 1998).
47. See generally 21 C.F.R. § 202.1.
48. 21 U.S.C. § 352(n)(3)(2000).
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and precautions under the headings "cautions," "special considerations," "important notes," and "effectiveness. 4 9 At the end of the
day, the "brief summary" generally must include all of the language
contained in the product's package insert.50
This language, commonly provided in eye-straining "mouseprint," is lengthy, technical, and detailed to the point of incomprehension for the average layperson. In fact, the technical nature of
this language is one of the main reasons for the learned intermediary rule-only a physician is properly qualified to understand, digest, and translate such highly technical information in terms her
patients can understand.
The regulations for advertising prescription drugs through
broadcast audio such as television or radio modify the disclosure
requirements. Recognizing that the length of a "brief summary"
would make radio and television advertising impossible, FDA limited the disclosure requirements in the broadcast media to a "major
statement" of the risks attendant to the therapy. 5' Also, in lieu of
presenting a "brief summary" in connection with the ad, a sponsor
may provide a way for the viewer to obtain the approved package
labeling outside the broadcast presentation." This alternative is
known as "the adequate provision" requirement.
While the adequate provision requirement made broadcast advertising more accessible to drug and device manufacturers on paper, manufacturers did not seize the opportunity because FDA was
silent on how the requirement could be satisfied. Without some assurances from the agency, manufacturers found the risk that their
advertising would be found in violation of the FDCA-which would
lead their product to be considered "misbranded" and subject to
seizure-were simply too great.
Thus, in August of 1997, FDA addressed manufacturers' fears
by publishing a draft guidance entitled "Consumer-Directed
Broadcast Advertisements," which sets out criteria for the "adequate
provision" of labeling information.5 ' The agency issued the final
guidance, which does not differ substantially from the draft, on
49.
50.
51.

21 C.F.R. §§202.1(e) (1), (e) (3) (iii).
See generally 21 C.F.R. § 202.1 (e) (3), (e)(4).
21 U.S.C. § 202.1(e)(1).

52. Id.
53. FinalGuidancefor Industry; Consumer-Directed Broadcast Advertisements;
www.fda.gov/cder/guidance/1804fnl.pdf; see also FDA Talk Paper, FDA Issues Final
Guidance for Direct-to-Consumer Rx Drug Advertisements (August 6, 1999),
www.fda.gov/bbs/topics/ANSWERS/ANS00968.html
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August 6, 1999. 54 In the guidance suggests a four-part approach:

1. The ad should include a toll-free telephone number for
consumers to call for the approved package labeling.55 Following
their call, consumers should be given the choice of receiving the
56
labeling by mail, fax, or by having it read to them over the phone.
2. The ad should indicate that additional product information
is available in print advertisements or brochures. 5' This provides a
mechanism for consumers who do not have internet access to obtain the labeling. Thus, the broadcast ad could refer consumers to
a print ad containing a "brief summary," or direct them to brochures available at doctors' offices, libraries, and pharmacies.
3. The ad should state that pharmacists and/or physicians may
provide additional product information to consumers.
4. The ad should provide an internet address, either during
the broadcast or throuh the toll-free number, where consumers
can access the labeling.
An ad containing these elements should meet the "adequate
provision" requirement, assuming it also includes a thorough "major statement" conveying the product's most significant risks.
B.

Implications Of Direct Advertising For The Learned Intermediary
Doctrine

In the old marketing regime, prescription products were only
marketed to physicians, and only physicians received warnings information about the product. This was consistent with the principles underlying the learned intermediary doctrine, through which
a manufacturer discharges its duty to warn by informing physicians-and not health-care consumers-of risks associated with the
medication. 59 Where products are the subject of direct advertising,
however, the applicability of these principles is called into question.
The learned intermediary doctrine assumes that consumers

Final Guidancefor Industry; Consumer-Directed Broadcast Advertisements;
www.fda.gov/cder/guidance/1804fnl.pdf; see also FDA Talk Paper, FDA Issues Final
Guidancefor Direct-to-ConsumerRx Drug Advertisements (August 6, 1999),
www.fda.gov/bbs/topics/ANSWERS/ANS00968.html
55. Id. at 2.
56. Id.
57. Id. at 2-3
58. Id. at 2.
59. Joseph G. Blute, Courts Struggle with Learned IntermediaryRule Exceptions, XV
Leader's Product Liability Law & Strategy 3 (May 1997).
54
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must have a doctor navigate them through the complex medical
and scientific issues presented by prescription drug treatment.
Thus, the manufacturer's duty is limited to providing adequate
warnings to the physician, who has a corresponding duty to translate that information in terms that her patients will understand.
Exceptions to the doctrine have emerged over the years with
respect to mass immunizations, oral contraceptives, and Intrauter60
ine contraceptive devices (IUDs). Courts have reasoned that since
mass immunizations are not usually administered by physicians, little specialized information is conveyed to the patient, and therefore manufacturers must warn consumers directly of any risks. 6'
With respect to oral contraceptives and IUDs, courts have held that
since patients ultimately decide for themselves which form of birth
control to use, they must be warned directly in that instance as
well.62
The rationale behind each of these exceptions is that the consumer, and not the physician, ultimately drives the decision
whether to obtain the product, and that the doctor's role in providing specialized information is diminished. This rationale is cited in
support of arguments that manufacturers lose the learned intermediary defense when they engage in direct-to-consumer advertising.
1. Some Courts ConsiderDTC Advertising Another Exception To
The Learned IntermediaryDoctrine
63
Edwards v. Basel Pharmaceuticals
is an example of a case where

the court held DTC advertising was an exception to the learned intermediary doctrine. In Edwards, the decedent suffered a fatal
heart attack which allegedly resulted from overuse of a nicotine
patch. The package insert specifically disclosed the risk of death
from overdose, but the direct-to-patient warnings did not. The
manufacturer asserted that, consistent with the learned intermediary doctrine, its liability for failure-to-warn could only be assessed
with respect to the physician-directed package insert.
The Oklahoma Supreme Court disagreed. Despite the full
warning in the package insert, the court held that:

60.

Id.

61.
62.
63.

Id.
Id.
933 P.2d 298 (Okla. 1997).
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When direct warnings to the user of a prescription drug
has been mandated by a safety regulation promulgated for
the protection of the user, an exception of the learned intermediary doctrine exists, and failure on the part of the
manufacturer to warn the consumer can render the drug
unreasonably dangerous. 64
In Shanks v. Upjohn Co., 65 a case involving the drug Xanax, the

court held that prescription products where patients initiate the
usage, where drugs are typically administered in a clinical setting
with little patient input or where drugs marketed under a strategy designed to appeal directly to the consuming public are areas where courts
have held
that manufacturers have a duty to warn patients di66
rectly.

In In Re Norplant Contraceptive Products Liability Litigation,67 a
federal court in Texas held that the defendant's direct advertising
campaign for Norplant, an implantable contraceptive, did not
eliminate the learned intermediary defense because the plaintiffs
never saw any of the ads before receiving their implants. But the
court did not address the question "[w]hether a drug manufacturer's use of direct-to-consumer advertising is ever grounds for creating an exception to the learned intermediary doctrine," indicating that "This is an issue which should be resolved by the Texas
Supreme Court."68
Finally, in another Norplant case, Perez v. Wyeth Laboratories,
Inc.,69 the New Jersey Supreme Court held that direct-to-consumer
advertising creates an exception to the learned intermediary rule.
The Court expressed its view that "Our medical-legal jurisprudence
is based on images of health care that no longer exist" in ruling
that the underpinnings of the learned intermediary doctrine are
absent in the context of consumer-directed advertising."' Unlike in
the past, doctors have less time to discuss risks with patients, and
drug companies have much greater access to consumers through
direct advertising; therefore, the Court reasoned, manufacturers
should be held liable if their advertising fails to provide adequate

64.
65.
66.
67.
68.
69.
70.

Id.
835 P.2d 1189 (Alaska 1992).
Id. at 1195, n.7.
955 F. Supp 700 (E.D. Tex. 1997).
Id. at 708, n. 45 (emphasis added).
734 A.2d 1245 (N.J. 1999).
Id. at 1246, 1255.
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warnings. 71 The Court did suggest, however, that compliance with
FDA regulations governing consumer-directed advertising would be
a defense to a failure-to-warn claim. 2
2. Despite These Holdings, The Learned Intermediary DoctrineIs
Still Alive In MostJurisdictions
7
In Polley v. Ciba-Geigy Corporation,
' a federal court in Alaska ap-

plied the learned intermediary doctrine despite direct communications in patient brochures. The court held that the brochures did
not create an exception to the learned intermediary rule. Mikell v.
Hoffman-LaRoche, Inc.14 held similarly. There, an informational
pamphlet identifying some, but not all risks associated with the
drug Accutane did not void the learned intermediary defense since
the plaintiffs prescribing physician was aware of the risk when he
wrote the prescription.
In Presto v. Sandoz Pharmaceuticals Corporation, the Georgia
Court of Appeals concluded that a pamphlet entitled, "Understanding Clozaril (Clozapine) Therapy: A Guide For Patients And Their
Families," did not nullify the learned intermediary doctrine because the plaintiffs could not have reasonably relied on the pamphlet for warnings concerning the dangers of the use of Clozaril.
According to the court, "[t] he pamphlet does not constitute an effort to inform patients of all the dangers of Clozaril and does not
purport to do so....The booklet states that it 'provides answers to
many questions about Clozaril' but cautions the reader 'if there are
other questions about76 Clozaril therapy, be sure to ask the doctor,
nurse or pharmacist.'
These decisions seem more in tune with health-care decisionmaking today. Even with the increase in information available directly, consumers still need a doctor to balance the benefits against
the risks and to provide expert advice on whether the therapy is
appropriate. While direct advertising creates a more educated public, it can never replace the particularized information that physicians provide, and it therefore should not relieve doctors of their
duty to inform their patients.
71.
72.
73.
74.
75.
76.

Id. at 1255-57.
Id.at 1259.
658 F. Supp. 420 (D. Alaska 1987).
649 So. 2d 75 (La. Ct. App. 1994).
487 S.E.2d 70 (Ga. 1997).
Id. at 74.
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C. A Related Issue: "Med Guides"

The issue of manufacturers' responsibility to provide warnings
to consumers arose before the ascendance of direct-to-consumer
advertising. In 1995, FDA proposed a rule that would require
manufacturers to produce "med guides" for their products, along
the lines of the "Nutrition Facts" labeling provided on food products." The guides would have replaced the often inconsistent pamphlets provided by pharmacies, and their language would have required FDA approval."
Faced with strong protests from pharmacies and drug companies concerned about the increased liability the "med guides"
7
plan in 1997. ,
would create, Congress rejected the comprehensive
But FDA has recently gone forward with a less ambitious plan to
require such guides for 10 drugs it considers particularly dangerous
in a given year."° Further, under new Department of Health and
Human Services regulations, 75% of all prescriptions must come
with leaflets containing "useful information" by the end of 2000,
and 95% by 2006-otherwise, FDA promises to reintroduce its med
guides plan.8' As doctors, under pressure from managed care payers, have less and less time to discuss risks of medications with their
patients, Congress may have no choice but to adopt the program
the next time around. Clearly, the consequences would be grave
for the learned intermediary doctrine.
IV.

DISSEMINATING INFORMATION ON OFF-LABEL USES: ILLEGAL

PROMOTION, OR FREE SPEECH?

The increased volume of drug and medical device advertising
belies the fact that medical products marketing is often a regulatory
high-wire act. When FDA approves a medical device or pharmaceutical, it allows sale of the product for the approved indications
and for those indications only. Thus, although doctors frequently
discover new and highly beneficial uses of approved products, drug
and device companies are not allowed to market the products for
those uses without going through the FDA approval process all over
77.

60 FR 44181 (August 24, 1995); see also Sheryl Gay Stolberg, FDA Pushesfor

PrescriptionDrug Guides, N.Y. Times, June 4, 1999.

78.
79.
80.

Stolberg, supra note 77.
Id.
Id.

81.

Id.
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again.8 2 Doctors, however, remain free to prescribe medication for
unapproved uses, a practice known as "off-label use."" For example, doctors for years have prescribed aspirin in order to reduce the
risk of heart attacks, but this "off-label" use was not actually approved by FDA until 1998.84 The pharmaceutical industry estimates
that anywhere from 25% to 60% of the 1.6 billion prescriptions
written annually are for off-label uses.815
Sometimes doctors who discover such beneficial "off-label"
uses publish their results, so that others in the health care community may benefit. But when a manufacturer provides a doctor with
such articles, is the manufacturer "promoting" its product for the
off-label use? Or is the manufacturer merely exercising its freespeech right to provide the doctor with truthful information?
A.

86
Round 1: Washington Legal Foundation vs. Friedman

For the last five years, FDA has taken a strict stance that a
manufacturer's mere distribution of information on off-label useseven without any endorsement or comment of any sort-constitutes
illegal marketing and renders the product in question "misbranded." It took this stance in three separate publications:
-Guidance to Industry on Dissemination of Reprints of Certain Published, Original Data, 61 FR 52800 (October 8, 1996);
-Guidance for Industry Funded Dissemination of Reference
Texts, 61 FR 52800 (October 8, 1996); and
-Final Guidance on Industry Supported Scientific and Educational Activities, 62 FR 64074 (December 3, 1997).
In Washington Legal Found. v. Friedman, the Washington Legal
Foundation ("WLF"), a non-profit organization favoring reduced
government regulation, sued the Agency on the ground that the
three guidance documents infringed on drug and device manufacturers' First Amendment rights.
WLF argued that the speech in question concerned academic
and scientific research, and was therefore entitled to the highest
First Amendment protection; the FDA responded that the guid82.
83.

21 U.S.C. § 321 (p).
59 FR 59820-21 (November 18, 1994).

84. Jim Oliphant, FDA's New Drug War Industry Fights ForAlternative Uses of Approved Productivity,Legal Times, January 10, 2000.
85. Id.

86.

13 F. Supp. 2d 51 (D.D.C. 1998) (hereinafter "WLF 1").

87.

Id.
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ances did not implicate the First Amendment, but if they did, the
speech at issue was "commercial" and should not be granted the
protection of "pure" speech. 8' First, the Court held that the guidances did constitute speech meriting some level of protection, notwithstanding FDA's argument that its broad regulatory authority
empowered it to regulate without running afoul of the First
Amendment. s9 Then, while recognizing that the dissemination of
off-label use information is "one of those complex mixtures of
commercial and non-commercial elements," the court found the
manufacturers' activities essentially promotional and worthy of only
the qualified protection afforded commercial speech under Central
Hudson Gas v. Public Service Comm'n of New York. 447 U.S. 557

(1980)."
Applying the CentralHudson Gas test, Judge Lamberth held:
1) that dissemination of off-label information is neither unlawful nor inherently misleading;
2) that the government has a substantial interest in protecting
the health of its citizens and in requiring manufacturers to submit
off-label uses for FDA approval;
3) that the guidance documents advance the government's
substantial interests; but
4) that the guidance documents are unconstitutional because
they are more extensive than necessary.91
Thus, the court found that "[t]hrough the government's wellintentioned efforts to prevent misleading information from being
communicated, a great deal of truthful information will also be
embargoed. 9 2 According to Judge Lamberth, an "obvious" and less
restrictive alternative to the Continuing Medical Education
("CME") guidances-which would have prohibited manufacturers
from distributing articles on off-label topics-is to allow the distribution but with "full, complete, and unambiguous disclosure by the
manufacturer" that the materials concern an off-label use.9 Based
on this reasoning, he issued an injunction barring FDA from limiting "any pharmaceutical or medical device manufacturer or any
other person":

88.
89.
90.
91.
92.
93.

Id. at 59.
WLFIat 59-61.
Id. at 62-65 (citations omitted).
Id. at 65-74.
Id. at 73.
Id.
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...
from disseminating or redistributing to physicians or

other medical professionals any article concerning prescription drugs or medical devices previously published in
a bona fide peer-reviewed professional journal, regardless of
whether such article includes a significant or exclusive focus on
uses of drugs or medical devices other than those approved by

FDA..94
B. Round 2: Washington Legal Foundation vs. Henney 95
The Guidance documents at issue in WLFIwere superseded by
the passage of the Food and Drug Modernization Act of 1997
("FDAMA"), which contains specific provisions governing manufacturer distribution of information on off-label uses. Since the
FDAMA came into effect after Judge Lamberth issued his injunction, FDA argued that the injunction should be modified to exclude FDAMA and its implementing regulations from the injunction's scope. The Judge instead amended the injunction to clarify
that the FDAMA provisions and related regulations, which were essentially the same as the three guidance documents at issue before,
were also unconstitutional.9 6
One subtle change instituted by the FDAMA was to permit
manufacturers to distribute off-label information, so long as they
made an application to FDA to have the use approved within a
short time of the distribution. But Judge Lamberth hardly agreed
that this removed the taint from the statute:
The supplemental application requirement of the act amounts
to a kind of constitutional blackmail-comply with the statute or
sacrifice your First Amendment rights. It should go without saying
that this tactic cannot survive judicial scrutiny.97
Thus, he concluded that the injunction should not be curtailed, but rather expanded to include the FDAMA and its implementing regulations.
C

Round 3: FDA Retreats - And Wins?

By what some would consider a legal Houdini-act, FDA man-

94.

Id.

95.
96.
97.
98.

56 F. Supp. 2d 81 (D.D.C. 1999) (hereinafter W FIf).
Id. at 82.
Id. at 87.
Id. at 88.
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aged to escape the full impact of Judge Lamberth's decisions and
injunctions in VVLF I and VLF Hat the Court of Appeals. In argument before the D.C. Circuit, the Agency essentially stipulated that
the FDAMA, along with its guidance on industry-supported CME,
did not provide it with independent authority to prohibit dissemination of information about off-label uses of drugs and medical devices. The Court of Appeals therefore found, and WLF agreed, that
there was no longer a First Amendment issue to be decided, and
vacated Judge Lamberth's decisions and injunctions in VLFIand /
to the extent they declared FDAMA and the CME guidance unconstitutional. 99 In partly vacating the district court's orders, the D.C.
Circuit made it clear that "[w] e certainly do not criticize the reasoning or conclusions of the district court.. .we do not reach the
merits of the district court's First Amendment holdings and part of
its injunction still stands."'0 0 What the Court did not make clear,
though, is which part of the injunction remains standing.
FDA did not "fall on its sword" before the Court of Appeals for
no reason. It is now apparent that the agency conceded that
FDAMA and the CME guidance do not independently allow speech
restrictions in order to preserve a foothold, however tenuous, for
maintaining regulatory authority over information about off-label
uses. Thus, in spite of the Appeals Court's approbation (albeit in
dicta) of Judge Lamberth's reasoning, the Agency remains loyal to
its original position, insofar as it intends to use non-compliance
with FDAMA and the CME guidance as evidence in "misbranding"
actions against manufacturers. The D.C. Circuit's opinion supports
the agency's authority to proceed in this manner, holding that
"[t]he FDA retains the prerogative to use both types of arguably
promotional conduct as evidence in a misbranding or 'intended
use' enforcement action."' 0' Consequently, even though the agency
may not be able to prevent manufacturers from distributing information about off-label uses, it may still argue that such distribution
indicates an intent to promote a use other than the uses in the approved labeling-unless, of course, the distribution falls within the
boundaries established by FDAMA and the CME guidance. At the
same time, the Agency recognizes that a manufacturer may have a
First Amendment defense in a "misbranding" action based on non-

99.

Washington Legal Found. vs. Henney, 202 F.3d 331 (D.C. Cir. 2000).

100.

Id. at 336.

101.

Id.
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compliance with these requirements. 12
Under these circumstances, even though the agency's concession is an apparent victory for WLF, the organization remains circumspect about FDA's intent to comply with the spirit of Judge
Lamberth's decisions. WLF Chief Counsel Richard Samp indicated
that " [w] e will be keeping a close eye on FDA; the very first time
FDA so much as suggests that manufacturers could be sanctioned
for distributing truthful information of the type covered by the injunction, we will
be back in district court seeking to have FDA held
10 3
in contempt."

The Agency has now made the first such suggestion, reiterating its position in the Federal Register of March 16, 2000 that the
FDAMA and the CME guidance establish a "safe harbor" for manufacturers who comply with them, but insisting that it may still use a
manufacturer's non-compliance as evidence of a medical product's
true "intended use" in an action for misbranding.104 WLF disagrees
with this interpretation and reportedly intends to make a motion to
enforce Judge Lamberth's earlier order, which in WLF's view still
bars the agency from prohibiting the dissemination of information
on off-label uses. Clearly, the fight isn't over; quite possibly it has
just begun.
V.

INDUSTRY GIFTS To PHYSICIANS: SUPPORTING INNOVATION OR
"BUYING SCIENCE"?

As medical device and pharmaceutical manufacturers have intensified their marketing efforts, they have developed new ways to
broaden their relationships with doctors. The orthopedic bone
screw litigation of the late 1990's illustrates the perils of these marketing strategies if the product later becomes the subject of litigation.
The bone screw litigation involved more than 2,000 civil actions from all over the country that were consolidated for pre-trial
purposes in the U.S. District Court for the Eastern District of Pennsylvania. 11 5 The plaintiffs claimed to have suffered injuries from allegedly defective rods, plates, and screws placed in their spine in

102. 65 FR 14287 (March 16, 2000).
103. WLF Press Release, Appeals Court Affirms Injunction Against FDA Speech Restrictions, at <http://www.wlf.org/pressrel.htm> (last visited Feb. 11, 2000).
104. 65 FR 14287 (March 16, 2000).
105. In re Orthopedic Bone Screw Litig., 193 F. 3d 781, 784 (3d Cir. 1999).
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order to alleviate their severe back conditions. °6 But more than a
year after the first complaints were filed, the plaintiffs expanded
their claims beyond the well-worn products liability theories typically found in medical mass torts. In these "Omni" actions, the
plaintiffs alleged that the manufacturers, certain medical professional associations, and individual doctors conspired to hoodwink
the FDA and defraud hundreds of orthopedic surgeons who would
not have implanted the devices into the plaintiffs had they known
the real risks of the procedure.' ° The allegations amounted to a
claim that the device industry and the medical profession had conspired to "buy the science" that would support ongoing sales of
bone screw devices.
The alleged conspiracy was based on agreements between the
manufacturers, the medical associations, and the doctors that the
doctors would make presentations on spinal fixation of the device-an unapproved, "off-label" use-in exchange for royalties relating to sales of the product and for shares in the manufacturers'
companies.'O" According to the complaints, although the seminars
did not on the surface appear different from other CME programs,
they really amounted to "Tupperware parties" since their purpose
was purely commercial.1 9 The doctors did not disclose to seminar
attendees that the procedure they were demonstrating was "offlabel" and not approved by the FDA, nor did they disclose their direct financial interest in the success of the product and the company that made it.""
While the "Omni" conspiracy claims were dismissed with
prejudice,"' they nevertheless are significant as a first salvo fired
into uncharted territory. The manufacturers, medical associations,
and doctors named in the suits spent millions fending them off.
The suits also exposed the extent to which industry promotional
practices pervade continuing medical education events, a revelation that is troubling to many. While the plaintiffs' bar lost this
time, they no doubt learned valuable lessons in the bone screw litigation-lessons that could reverse their fortune the next time
around.

106.
107.

Id.
Id. at 786.

108.
109.
110.
111.

Id.
Id.
Id. at 786-77.
Id. at 792.
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Influence In Practice: TheJAMA Study On Physician Gifts And
PrescribingPractices

One piece of evidence that future conspiracy plaintiffs will
likely use is a January, 2000 study published in the Journal of the
American Medical Association on the influence of gifts on physicians'

prescribing practices.1 2 The study, a compilation of data from 538
other studies on the subject, resulted in the following startling conclusions:
Meetings with pharmaceutical representatives were associated
with requests by physicians for adding the drugs to the hospital
formulary and changes in prescribing practice.
Drug company-sponsored continuing medical education
(CME) preferentially highlighted the sponsor's drug(s) compared
with other CME programs.
Attending sponsored CME events and accepting funding for
travel or lodging for educational symposia were associated with increased prescription rates of the sponsor's medication.
Attending presentations given by pharmaceutical representative speakers was also associated with non-rational prescribing."3
In Commentary published in the same issue as the study, Dr.
Robert M. Tenery notes that many doctors are not even aware of
the extent of influence that industry-sponsored activities and gifts
have on their prescribing practices." 4 He advocates that:
Even though it may be desirable to encourage information sharing, relationships between physicians and industry raise concerns about whether the patient's best interests will come into conflict with industry's focus on the
bottom line. Physicians should not take as absolute everything they are told by industry representatives and should
become cognizant of the potential conflicts created by the
increasing level of sophistication in the detailing techniques used by these individuals.' |5

112. Ashley Wazana, M.D., Physicians and the PharmaceuticalIndustry: Is a Gift
EverJust a Gift?, 283 JAMA 373 (2000).
113. Id. at 375-377.
114. Robert M. Tenery, Jr., M.D. Interactions Between Physicians and the Health
Care Technology Industy, 283 JAMA 391 (2000).
15

id.
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Expanding The Sphere Of Influence: "Detailing"To Nurse
PractitionersAnd Physicians'Assistants

Today, manufacturers' promotional efforts extend well beyond
physicians, as seen in the discussion of direct-to-consumer advertising. But even within the medical community, doctors are no
longer the exclusive focus of drug marketers. As Nurse Practitioners (NP) and Physicians' Assistants (PA) receive ever-greater prescribing authority, pharmaceutical and medical device "detailers"
are targeting them with more and more, promotional efforts. Some
physicians find this a cause for concern.
While non-physician prescribers, like doctors, insist that company representatives are only one source of their information on
medical products, they are nonetheless subject to a barrage of sales
pitches. A survey by Scott-Levin Associates revealed that PAs averaged 4.4 visits per week from detailers, and NPs averaged 5.2.17
These visits are only expected to increase. "8
In addition to the frequency of the visits, there is a concern
that nurse practitioners and doctors' assistants are particularly susceptible to "hard sell" efforts by medical products retailers. One
commentator claims that such "physician extenders" do not have
"the knowledge base to understand pharmacology and the complexities of medicine.""9 He quips that "[t] hey are given samples of
advanced antibiotics, invited out to dinner and are being prepped
to use these samples.' ' 20 Fearing that "drug companies are simply
looking for the weakest link in the practice," he postulates that
nurse practitioners and physician assistants are being targeted because they are "most likely to comply with marketing and sales messages.
Whether non-physician prescribers are this easily swayed by detailers can be argued, but there is no disputing the fundamental
shift in the demographics of medical products sales. As marketing
to non-physicians escalates, doctors are less available to company
salespeople than ever before. 22 In addition, as consumers receive
116.
(March
117.
118.
119.
120.
121.
122.

Jay Greene, Drug Reps Targeting Nonphysicians, American Medical News
27, 2000).
Id.
Id.
Id.
Id.
Id.
Jay Greene, Drug Reps Targeting Nonphysicians, American Medical News

Published by Mitchell Hamline Open Access, 2000

23

William Mitchell Law Review, Vol. 27, Iss. 1 [2000], Art. 25
WILLIAM MITCHELL LA W REVIEW

[Vol. 27:1

more advertising messages about new products, they specifically request certain name-brand medications, and primary care physicians, given their time constraints,
are increasingly delegating such
23
requests to their assistants.

Further, according to the Scott-Levin survey, 80% of PAs and
69% of NPs recommend new drugs to the doctors with whom they
work, 12 4 which may influence the extent to which these products are
ultimately prescribed. At the same time, Dr. Yank Coble of the
American Medical Association expressed that "I don't get my information on new drugs from nurses, and I don't think many other
doctors do either.', 125

Thus, it remains unclear just how much

stepped-up marketing to non-physicians has actually influenced
prescribing practices.
It is also worth noting, however, that the increase in nonphysician prescribing, along with the intensified sales efforts directed at PAs and NPs, could have dire consequences for the
learned intermediary doctrine. If it is indeed "unrealistic," as Dr.
Coble claims, "to suddenly expect people with less training than
doctors to interpret research for patients,'' 26 then courts will have
no choice but to ignore the learned intermediary doctrine and require manufacturers to provide warnings directly to consumers.
VI. REPROCESSING AND REUSE OF SINGLE USE DEVICES

With the increased cost-control pressures of managed care,
along with the ascendance of for-profit hospitals, providers today
have every incentive to cut costs wherever they can. Thus, many
providers have begun cleaning ("reprocessing") and returning to
circulation so-called "single-use" medical devices. Hospitals and
medical centers can save tens of thousands of dollars per year by
reusing such devices. 12 Further, doctors argue that the prices
manufacturers charge are so prohibitive that they cannot afford to
use a device just once, and costs cannot be passed along to patients
because the rates are usually set by insurance companies or medi-

(March 27, 2000).
123. Id.
124. Id.
125. Id.
126. Id.
127. Gina Kolata, "Single Use" Medical Devices Are Often Used Several Times, N. Y.
Times, November 10, 1999.
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care. 12 Dr. David Haines of the University of Virginia Health System claims that if they were forced to use cardiac catheters only
once, as the manufacturer's labeling directs, "we would shift from
being marginally profitable to probably losing $600,000 a year."
Many also point to the fact that some devices initially labeled "reusable" were switched to "single-use" without any structural changes,
making it appear that the switch had more to do with marketing
than safety.
While Dr. Larry Kessler, director of the office of surveillance
and biometrics at FDA, acknowledges that "there's a big yuck factor
to reusing devices," he maintains that nevertheless "there are no
products where we have significant evidence that there is immediate harm to public health."'3' Published studies by Dr. Richard A.
Kozarek, chief of gastroenterology at Virginia Mason Medical Center in Seattle, show that various devices can safely be reused numerous times, generating a substantial savings for health-care providers." Further, of the more than 100,000 yearly adverse reports
concerning devices, virtually all involve devices used just once.13
Of course, as Dr. Kessler acknowledges, if a reprocessed device
failed, "[d]o you think the hospital would want to tell anyone?
They 3are worried that they will be in court and in serious trou13
ble."
So far, FDA has refrained from requiring reprocessors of single-use devices to prove that the products are "safe and effective"
when they leave their hands, but this may change as medical device
manufacturers are increasingly challenging the practice. 3 4 Despite
charges that the industry's complaints are motivated by their profit
margins, medical device manufacturers argue that the real issue is
patient safety. 3 5 Patricia Davis, an electrical engineer and senior
patent attorney at Boston Scientific, a leading manufacturer of
coronary stents, claims that studies by her company indicate that
devices are often contaminated and degraded when they leave the

128. Id.
129. E.g., Congressional Testimony of Vern Feltner, February 10, 2000, 2000
WL 11068076.
130. Gina Kolata, "Single Use" Medical Devices Are Often Used Several Times, N.Y.
Times, November 10, 1999.
131. Id.
132. Id.
133. Id.
134. Id.
135. Id.
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reprocessor.136 She warns that subtle changes in a device's functioning upon reuse can have devastating consequences for patients."'
Another commentator raises the concern that since single-use devices are not made to be cleaned and reused, "the very design structure did not take into account the need to access all the nooks and
crannies in order to clean them.',13 This increases the
risk of infecof.L 39
tion, which he claims patients should be informed

Robert O'Halla, Vice President of Regulatory Affairs for Medical Devices and Diagnostics atJohnson &Johnson and Chairman of
the Association of Disposable Device Manufacturers, argues that
there is no reason to treat reprocessors differently than original
equipment manufacturers (OEMs) . OEMs are required to obtain
either 510(k) clearance or pre-market approval for their single-use
devices. 141 When they are approved, they are approved for one use
only, since no data supports their safety and efficacy beyond that.
Therefore, when a reprocessor prepares a device for reuse, as a
regulatory matter this is tantamount to creating a new device."' Yet
to this point, FDA has exercised its "regulatory discretion" to not
require reprocessors to submit 510(k) or pre-market approval applications-even while recognizing that the same provisions of the
Food, Dru 4& Cosmetic act that apply to OEMs also apply to reprocessors.
Under increased pressure from manufacturers, and recognizing the inconsistency of their position, FDA is in the process of
formulating regulations for reprocessing of single-use devices. In
testimony before Congress, Dr. David Feigal, Director of FDA's
Center for Devices and Radiological Health (CDRH), indicated
that the Agency plans "a new regulatory approach that will treat
136. Gina Kolata, "Single Use" Medical Devices Are Often Used Several Times, N.Y
Times, November 10, 1999.
137. Id.
138. Congressional Testimony of Philip Grossman, M.D., February 10, 2000,
2000 WL 11068079.
139. Id.
140. Congressional Testimony of Robert H. O'Holla, February 10, 2000, 2000
WL 11068080.
141. 510(k) clearance may be obtained by showing that a new device is
"substantially similar" to one already shown to be safe and effective. See generally 21
C.F.R. § 807, Subpart E. Pre-market approval requires much more extensive testing to show that the device actually is safe and effective. See generally 21 C.F.R. §
814, Subpart B.
142. Congressional Testimony of Robert H. O'Holla, February 10, 2000, 2000
WL 11068080.
143. Id.
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Original Equipment Manufacturers... third parties and hospitals in
a similar manner to minimize risks associated with reused single-use
devices.'1 4 For now, FDA is receiving comments on its February 8,
2000 draft Guidance which presents a "Review Prioritization
Scheme" for assessing the safety of reprocessing different categories
of devices.145 Through a series of flow charts, devices will be characterized as low, medium, and high risk for reprocessing based on
answers to questions like:
Does postmarket information suggest that using the reprocessed SUD [(single-use device)] may present an increased risk of
infection when compared to the use of a SUD that has not been
reprocessed?
thorough
Does the SUD include features that could impede
46
cleaning and adequate sterilization/disinfection?1
Other countries are also evaluating the use of single-use devices. Canada is conducting a review of the practice after the province of Manitoba instituted a ban on hospital reprocessing. 4' Belgium is considering a ban on reuse of angioplasty balloons,
electrophysiology catheters, biopsy141forceps and other delicate deIn the United Kingdom, the
vices used in invasive procedures.
Medical Device Agency has taken a stance against reuse due to a
concern149with the transmission of Creutzfeld-Jakob or "mad cow"
disease.

Of course, while reprocessors face liability for contaminated
devices that leave their cleaning facilities, manufacturers may ultimately bear more of the burden for injuries resulting from failures
of reprocessed devices. When reports of injuries from reused devices started to accumulate, instead of questioning reprocessors on
the adequacy of their procedures, FDA suggested that OEMs
should compile data on risks associated with reprocessing and reuse. 50 In addition, since manufacturers will often more capitalized
144.

Congressional Testimony of David W. Feigal, February 10, 2000, 2000 WL

11068073.
145. Guidance for Industry and FDA Reviewers, Reprocessing and Reuse of SingleUse Devices: Review Prioritization Scheme (February 8, 2000), www.fda.gov/cdrh-

reuse/cdrh/reuse/1 156.pdf.
146. Id.
147.

Canada Examining Single-Use Device Reuse Activity, International Regs, The

Gray Sheet, 2000 WL 8529412 (February 28, 2000).
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than reprocessing operations, they will inevitably be a target in litigation stemming from such injuries. Finally, manufacturers could
be found negligent for not guarding against "foreseeable misuse"
by providing instructions for proper cleaning, and for not making
devices sturdy enough for reuse-notwithstanding the "single use
only" warning-because they will usually have actual or constructive
knowledge that purchasers are reusing their products. Whether
the medical manufacturing industry can reduce this exposure by
pressuring FDA to adopt "pre-market approval" regulations, requiring reprocessors to prove the safety and efficacy of reused devices,
remains to be seen.
VII. CONCLUSION

The future of drug and medical device litigation promises to
be as contentious as the past, although the issues have changed.
Where the last 50 years saw the growth of the law with respect to
the healthcare product, in the future-as this discussion has shown
-new developments in the law will come more from the relationships surrounding the product: between industry and the consumer, between physician and industry, between industry and the
FDA, and even between rival healthcare industries. What will remain unchanged, however, is the intensity of the conflict as the law
struggles to reconcile itself with the new realities of medical technology in the 21i t Century.
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